OakChart

Nephros Inc

NEPHHealthcare·Medical Instruments & Supplies·USA·Nano·NASD·Nov 11 • 3:54 PM ET

3.07-0.08 (-2.54%)
2026-11-12 03:35 CET
Market cap
33.37 USD m
Revenue, TTM
21.58 USD m
Net income, TTM
1.91 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
0.17
P/E
17.88
Compare

Price

NEPH against its 20, 50 and 200-day averages
2050200beat
3.003.504.004.50124K248KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NEPHclose 3.0720-day 3.3350-day 3.72200-day 3.613.0752w low

52.2% under the 52-week high of 6.42 on 26 Nov 2025. 52-week low 2.66 on 7 Apr 2026. Last 15 sessions, 38.6% high to low

Volume 0.76× normal · the line is the 50-bar volume average

Profile

NEPH
52-week range, 11% of the way up
2.666.42

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Employees36
IPOSep 21, 2004
Beta1.75
ATR, 14d0.26
Rel volume0.76
Short float0.14%
Insider own19.47%
Inst own16.62%

Snapshot

6 groups

Valuation

Index-
Market Cap33.37M
Enterprise Value29.59M
Income1.91M
Sales21.58M
Book/sh1.15
Cash/sh0.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees36
IPOSep 21, 2004

Ratios

P/E17.88
Forward P/E11.37
PEG0.26
P/S1.55
P/B2.66
P/C7.33
P/FCF20.22
EV/EBITDA15.17
EV/Sales1.37
Quick Ratio3.45
Current Ratio5.50
Debt/Eq0.06
LT Debt/Eq0.03
Option/ShortNo / Yes

Earnings

EPS (ttm)0.17
EPS next Y0.27
EPS next Q0.02
EPS this Y69.70%
EPS next Y44.64%
EPS next 5Y44.22%
EPS past 3/5Y- -
Sales past 3/5Y23.50% 17.02%
EPS Y/Y TTM26.09%
Sales Y/Y TTM20.36%
EPS Q/Q49.84%
Sales Q/Q18.01%
EarningsNov 05 AMC
EPS/Sales Surpr.114.59% 2.37%

Ownership

Insider Own19.47%
Insider Trans0.00%
Inst Own16.62%
Inst Trans-38.66%
ROA13.39%
ROE16.95%
ROIC14.82%
Gross Margin60.00%
Oper. Margin8.48%
Profit Margin8.86%
SMA20-7.78%
SMA50-17.43%
SMA200-14.93%
Trades-

Technical

Shs Outstand10.87M
Shs Float8.75M
Short Float0.14%
Short Ratio0.28
Short Interest0.01M
52W High6.42 -52.18%
52W Low2.66 15.29%
Volatility8.75% 7.33%
ATR (14)0.26
RSI (14)40.83
Beta1.75
Rel Volume0.76
Avg Volume43.22K
Volume32,742

Performance

Perf Week-5.54%
Perf Month-14.48%
Perf Quarter-34.54%
Perf Half Y-13.52%
Perf YTD-37.09%
Perf Year-29.10%
Perf 3Y56.63%
Perf 5Y-59.87%
Perf 10Y6.60%
Recom1.67
Target Price6.08
Prev Close3.15
Price3.07
Change %-2.54%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jul 17, 2026InitiatedNNorthland CapitalMarket Perform$4+30.3%
Jan 26, 2021InitiatedRB. Riley SecuritiesBuy$12.50+307.2%

Peers

Mkt cap
TickerCompanyMkt cap
OMOutset Medical Inc78.61M
RMTIRockwell Medical Inc28.53M
UTMDUtah Medical Products Inc208.06M
CTSOCytosorbents Corp16.83M
HBIOHarvard Bioscience Inc44.06M
NUWENuwellis Inc2.99M
SNOASonoma Pharmaceuticals Inc5.94M
AEMDAethlon Medical Inc8.87M
STESteris Plc24.89B
SCWO374Water Inc40.19M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
WEXFORD CAPITAL LP10% OwnerAug 18 '26Option Exercise3.608122,92356,872Aug 20 04:14 PM
Banks Robert R. Jr.President and CEOMar 23 '26Option Exercise1.44120,000172,800190,000Mar 25 04:54 PM
Krandel JudyChief Financial OfficerMar 23 '26Option Exercise1.7168,861117,75268,861Mar 25 04:53 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 200
  • Nephros Beats Estimates, But Slowing Core Programmatic Growth Leaves Its Third-Quarter Results Looking Less Convincing (Earnings Whispers) -9.71%
  • Nephros Announces Strong Third Quarter 2026 Financial Results (GlobeNewswire)
  • Nephros Must Prove Record Quarter Was More Than A Tariff Refund (Earnings Whispers)
  • Nephros Schedules Third Quarter 2026 Financial Results Conference Call (GlobeNewswire)
  • Nephros Inc (NEPH) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge ... (GuruFocus.com) +17.27%
  • Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026 (GlobeNewswire)
  • Nephros Schedules Second Quarter 2026 Financial Results Conference Call (GlobeNewswire)
  • Nephros to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET (GlobeNewswire)
  • Nephros Announces Inclusion in the Russell Microcap Index (GlobeNewswire)
  • Nephros to Host Virtual Investor Event: "Beyond Filtration: The Nephros Model in Action" (GlobeNewswire)
  • Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water (GlobeNewswire)
  • Nephros Announces Financial Results for Quarter Ended March 31, 2026 (GlobeNewswire) +8.98%
  • Nephros Schedules First Quarter 2026 Financial Results Conference Call (GlobeNewswire)
  • Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.0500.0230.0505.625.493
2026Q22026-08-060.1100.0030.1086.024.993
2026Q12026-05-070.0100.0100.0135.215.022
2025Q42026-03-120.0100.0100.0064.734.452
2025Q32025-11-060.030-0.0200.0314.763.872
2025Q22025-08-070.020-0.0250.0224.403.652
2025Q12025-05-080.050-0.0050.0534.883.652
2024Q42025-03-060.0300.0300.0333.873.872
2024Q32024-11-070.020-0.0200.0173.523.502
2024Q22024-08-08-0.030-0.015-0.0283.253.852
2024Q12024-05-08-0.020-0.040-0.0163.513.712
2023Q42024-03-07-0.060-0.025-0.0623.303.812
2023Q32023-11-08-0.020-0.065-0.0173.743.372
2023Q22023-08-09-0.040-0.055-0.0423.553.102
2023Q12023-05-10-0.030-0.020-0.0303.703.681
2022Q42023-03-08-0.070-0.065-0.0892.602.812

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-0.540--0.5402.32-
2018FY-0.450--0.4975.69-
2019FY-0.450-0.547-0.45310.3310.02
2020FY-0.520-0.550-0.5258.568.59
2021FY-0.410-0.417-0.41010.4010.47
2022FY-0.420-0.695-0.7179.9810.29
2023FY-0.150-0.115-0.15214.2414.80
2024FY0.0100.0100.00714.1614.18
2025FY0.1100.1100.11018.7918.51
2026FY-0.187--22.24
2027FY-0.270--25.86
2028FY-0.330--29.09

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-093015.375.225.50
2026Q4S2026-11-063005.415.225.50
2026Q4S2026-10-213005.415.225.51
2026Q4S2026-08-173105.415.225.51
2026Q4S2026-08-073105.395.225.51
2026Q4S2026-07-163005.355.225.45
2026Q4S2026-05-272005.415.385.45
2026Q4S2026-05-152105.415.385.45
2026Q4S2026-05-082105.445.385.50
2026Q4S2026-03-162105.445.385.50
2026Q4S2026-03-131105.385.385.38
2026Q4S2026-01-211005.285.285.28
2026Q4S2025-11-111105.285.285.28
2026Q4S2025-11-101105.285.285.28

Estimate history

EPS, annual-0.138-0.497-0.453-0.525-0.41-0.717-0.1520.0070.1090.1717
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0170.0330.0530.0220.0310.0060.0130.1080.046
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual3.8095.68710.3348.56110.2179.97514.23814.16218.78921.58
Period201720182019202020212022202320242025TTM
Sales, quarterly3.5183.874.8774.4194.7644.7295.2126.0175.622
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual6.1447.188.0599.87310.25810.29710.54410.54510.64410.87
Period201720182019202020212022202320242025MRQ
Shares, quarterly10.54410.54510.610.60110.62710.64410.84310.8610.87
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue21.5818.7914.1614.249.9710.228.5610.335.69
Cost of Goods Sold Incl. D&A8.637.305.576.055.524.833.894.442.65
Gross Profit12.9511.488.598.194.455.394.675.903.04
Selling, General and Administrative Excl. Other11.1210.348.589.788.798.649.179.196.02
Research and Development1.441.340.910.871.241.492.763.091.54
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1.831.150.01-1.59-4.33-3.25-4.50-3.29-2.98
Interest Expense-0.000.000.000.020.040.110.200.17
Unusual Expense0.000.000.000.000.00-0.48-0.23-0.140.23
Net Income Before Taxes1.921.210.09-1.57-4.28-2.78-4.53-3.40-3.42
Income Taxes0.010.010.010.000.000.000.00-0.23-0.09
Consolidated Net Income1.911.190.07-1.57-4.55-3.02-4.77-3.42-3.40
Net Income From Continuing Operations1.911.190.07-1.57-4.55-3.02-4.77-3.42-3.40
Net Income1.911.190.07-1.57-7.38-4.11-4.77-3.42-3.40
EPS (Recurring)0.170.110.01-0.15-0.72-0.44-0.54-0.47-0.47
EPS (Basic, Before Extraordinaries)0.180.110.01-0.15-0.72-0.41-0.53-0.45-0.50
EPS (Diluted)0.170.110.01-0.15-0.72-0.41-0.53-0.45-0.50
EBITDA1.951.290.14-1.38-3.76-2.74-4.03-3.09-2.82
Non-Operating Income (Expense)0.100.060.080.020.080.03-0.14-0.05-0.03
Other After Tax Adjustments0.000.000.000.00-0.28-0.24-0.24-0.24-0.08
Stock Option Compensation Expense0.210.230.121.360.910.950.740.970.78
Price To Earnings Ratio17.8817.88-------
Price To Sales Ratio1.932.851.102.521.195.789.107.266.18
Gross Margin60.0061.1360.6457.5344.6452.7754.5557.0753.46
Operating Margin8.486.100.04-11.19-43.46-31.83-52.61-31.85-52.45
Net Margin8.866.350.52-11.06-74.01-40.20-55.67-33.09-59.82
Shares Outstanding10.8710.6410.5410.5410.3010.269.878.067.18
Market Capitalization33.3733.3715.5036.2811.9460.3884.6479.2336.83

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue5.626.025.214.734.764.424.883.87
Cost of Goods Sold Incl. D&A2.372.022.252.001.881.661.761.43
Gross Profit3.264.002.962.732.882.763.122.44
Selling, General and Administrative Excl. Other2.762.782.872.712.572.512.552.12
Research and Development0.330.370.350.400.340.310.290.25
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income0.501.210.100.020.310.250.570.32
Interest Expense0.000.000.00-0.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes0.511.210.140.060.340.250.560.36
Income Taxes0.000.010.000.000.000.010.000.01
Consolidated Net Income0.511.200.140.060.340.240.560.35
Net Income From Continuing Operations0.511.200.140.060.340.240.560.35
Net Income0.511.200.140.060.340.240.560.35
EPS (Recurring)0.050.110.010.010.030.020.050.03
EPS (Basic, Before Extraordinaries)0.050.110.010.010.030.020.050.03
EPS (Diluted)0.050.110.010.010.030.020.050.03
EBITDA0.531.240.130.050.350.280.610.35
Non-Operating Income (Expense)0.01-0.000.040.040.03-0.00-0.010.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.050.050.050.070.060.060.070.05
Price To Earnings Ratio17.8850.5026.9735.3437.8754.17252.94-
Price To Sales Ratio1.931.911.712.912.912.651.181.10
Gross Margin57.9366.4356.8757.7160.4762.4663.8763.07
Operating Margin8.9120.161.860.386.595.6111.618.19
Net Margin9.1119.892.691.317.075.3611.449.02
Shares Outstanding10.8710.8610.8410.6410.6310.6010.6010.54
Market Capitalization33.3738.7631.7251.8650.1443.3618.2315.50

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.403.764.313.636.978.254.174.582.19
Short Term Receivables2.411.781.501.291.641.361.271.450.88
Inventories3.232.622.473.154.465.302.561.860.67
Other Current Assets0.180.140.130.190.560.240.300.280.07
Total Current Assets11.228.308.408.2613.6315.158.308.173.81
Net Property, Plant & Equipment1.131.541.961.100.691.331.190.090.05
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable----0.030.040.030.000.05
Intangible Assets1.241.321.411.581.761.942.112.281.07
Other Assets0.050.050.090.051.570.050.000.020.00
Total Assets13.6411.2111.8611.0017.6518.5111.6310.564.98
Short Term Debt Incl. Current Port. of LT Debt0.390.350.450.390.560.561.031.190.71
Accounts Payable0.910.650.870.741.330.420.960.840.87
Income Tax Payable0.09---0.05----
Other Current Liabilities1.370.560.790.280.490.340.440.630.29
Total Current Liabilities2.771.562.111.412.391.322.432.651.87
Long Term Debt0.671.061.390.710.441.611.510.840.95
Provision for Risks Charges0.000.000.000.000.000.000.000.260.00
Other Liabilities0.000.000.000.000.070.000.000.000.21
Total Liabilities3.442.623.502.122.902.943.943.763.03
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity10.208.598.365.5911.7012.524.673.801.95
Total Shareholders Equity10.208.598.365.5911.7012.524.673.801.95
Accumulated Minority Interest0.000.000.003.293.053.053.013.000.00
Total Equity10.208.598.368.8814.7515.577.696.801.95
Total Liabilities & Stockholders Equity13.6411.2111.8611.0017.6518.5111.6310.564.98
Book Value Per Share0.960.810.790.541.141.270.580.530.32
Tangible Book Value Per Share0.840.690.660.390.971.070.320.210.14
Full-Time Employees363131273427251815
Price to Book Ratio2.661.904.211.895.186.7617.159.7091.98
Return on Assets9.610.64-13.78-31.78-16.73-31.63-30.83-43.78-21.12
Return on Equity12.710.87-22.58-52.68-24.97-55.43-80.73-118.37-61.83
Return on Invested Capital10.980.77-16.16-117.21-33.85-33.72-55.28-73.30-27.86
Quick Ratio2.893.642.813.623.847.432.362.381.68
Current Ratio4.065.313.985.855.7011.443.423.082.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income1.911.190.07-1.57-7.11-3.87-4.53-3.18-3.33
Depreciation0.120.140.140.210.700.570.520.200.16
Other Funds (Non Cash)0.670.720.851.362.940.990.601.281.35
Funds from Operations2.702.061.06-0.00-3.46-2.30-3.41-1.70-1.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.61-0.41-1.550.830.230.88-3.49-0.58-1.85
Cash from Operating Activities-0.911.65-0.490.83-3.23-1.42-6.90-2.28-3.66
Capital Expenditures0.000.00-0.06-0.07-0.14-0.04-0.24-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00-0.14-0.99
Sale of Fixed Assets and Businesses0.000.000.010.000.190.000.000.003.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-0.050.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.05-0.070.05-0.09-0.24-0.152.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.290.000.000.000.160.5011.622.743.92
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.290.000.000.000.160.5011.622.743.92
Proceedsfrom Stock Options0.000.000.000.000.000.0011.451.993.78
Issuance or Reduction of Debt, Net-0.01-0.01-0.01-0.08-0.29-0.26-0.32-0.630.13
Change in Long Term Debt-0.01-0.01-0.01-0.08-0.29-0.260.24-0.20-0.15
Issuance of Long Term Debt0.000.000.000.000.000.000.480.011.19
Reduction of Long Term Debt-0.01-0.01-0.01-0.08-0.29-0.26-0.24-0.22-1.34
Net Financing Active Other Cash Flow0.000.000.000.00-0.030.00-0.09-0.090.00
Other Financing Activities Uses0.000.000.000.00-0.030.00-0.09-0.09-
Cash from Financing Activities0.28-0.01-0.01-0.08-0.150.2411.222.024.05
Exchange Rate Effect---0.00-0.00-0.010.01-0.01-0.01
Net Change in Cash-0.621.64-0.550.67-3.34-1.284.08-0.412.39
Free Cash Flow-1.65-0.550.75-3.37-1.45-7.14-2.29-3.66
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-32.54-47.79-----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments4.554.704.025.405.175.07
Short Term Receivables3.584.103.522.412.662.04
Inventories4.954.553.623.232.742.24
Other Current Assets0.170.260.340.180.140.23
Total Current Assets13.2613.6011.5011.2210.719.58
Net Property, Plant & Equipment0.810.921.021.131.231.33
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.191.211.231.241.261.28
Other Assets0.050.050.050.050.050.05
Total Assets15.3015.7713.7913.6413.2512.24
Short Term Debt Incl. Current Port. of LT Debt0.430.410.400.390.380.37
Accounts Payable0.851.971.460.910.940.63
Income Tax Payable---0.09--
Other Current Liabilities1.130.960.661.371.150.77
Total Current Liabilities2.413.342.532.772.471.77
Long Term Debt0.350.460.570.670.770.87
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.763.803.093.443.242.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.5511.9710.7010.2010.019.60
Total Shareholders Equity12.5511.9710.7010.2010.019.60
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.5511.9710.7010.2010.019.60
Total Liabilities & Stockholders Equity15.3015.7713.7913.6413.2512.24
Book Value Per Share1.151.100.990.960.940.91
Tangible Book Value Per Share1.040.990.870.840.820.78
Full-Time Employees---36--
Price to Book Ratio2.663.623.115.185.224.67
Return on Assets13.3912.396.079.6112.5311.37
Return on Equity16.9516.107.7612.7116.2915.14
Return on Invested Capital3.979.631.240.573.132.26
Quick Ratio3.452.713.122.893.234.14
Current Ratio5.504.074.554.064.345.41

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income0.511.200.140.060.340.24
Depreciation0.030.030.030.030.030.03
Other Funds (Non Cash)0.160.170.150.190.170.19
Funds from Operations0.701.400.320.280.540.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.85-0.72-1.99-0.05-0.440.54
Cash from Operating Activities-0.150.68-1.670.230.100.99
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.290.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.290.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.00-0.00-0.00-0.00-0.00-0.00
Change in Long Term Debt-0.00-0.00-0.00-0.00-0.00-0.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.00-0.00-0.00-0.00-0.00-0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.00-0.000.29-0.00-0.00-0.00
Net Change in Cash-0.150.68-1.380.230.100.99
Free Cash Flow-0.15--0.230.100.99
Price to Free Cash Flow---33.2419.2122.15

Revenue breakdown

Product2024: 14.04M 2025: 18.23M
Royalty and Other Revenues2024: 127.00K 2025: 555.00K
United States2024: 14.16M 2025: 18.79M
Total Surgical & Medical Instruments & Apparatus revenue2024: 14.16M 2025: 18.79M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.14%0.0M8.8M36.93K
2026-10-150.18%0.0M8.8M29.23K
2026-09-300.29%0.0M8.8M21.77K
2026-09-150.53%0.0M8.8M20.94K
2026-08-310.44%0.0M9.4M19.07K
2026-08-140.48%0.0M9.4M16.15K
2026-07-310.40%0.0M9.4M18.49K
2026-07-150.33%0.0M9.4M21.36K
2026-06-300.34%0.0M9.4M23.14K
2026-06-150.21%0.0M9.4M32.12K
2026-05-290.27%0.0M9.4M36.19K
2026-05-150.22%0.0M9.4M39.33K
2026-04-300.32%0.0M9.4M39.82K
2026-04-150.45%0.0M9.3M43.38K
2026-03-310.49%0.0M9.4M48.98K
2026-03-130.06%0.0M9.4M44.86K
2026-02-270.04%0.0M9.4M51.42K
2026-02-130.11%0.0M9.4M55.41K
2026-01-300.10%0.0M9.4M61.12K
2026-01-150.08%0.0M9.4M63.99K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-08-06SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-14DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-14SEC
2026-10-138-KCurrent report2026-10-13SEC
2026-09-16SCHEDULE 13D/ASEC
2026-09-16SCHEDULE 13GSEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-158-KCurrent report2026-06-12SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-3010-K/A2025-12-31SEC
2026-03-278-KCurrent report2026-03-27SEC
2026-03-254Statement of changes in beneficial ownership of securities2026-03-23SEC
2026-03-254Statement of changes in beneficial ownership of securities2026-03-23SEC
2026-03-184Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-184Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-1210-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2025-11-268-KCurrent report2025-11-21SEC
2025-11-14SCHEDULE 13GSEC
2025-11-134Statement of changes in beneficial ownership of securities2025-11-10SEC
2025-11-134Statement of changes in beneficial ownership of securities2025-11-10SEC
2025-11-134Statement of changes in beneficial ownership of securities2025-11-10SEC
2025-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-08-134Statement of changes in beneficial ownership of securities2025-08-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
WEXFORD CAPITAL LP33.16%
Topline Capital Management, LLC4.93%
VANGUARD CAPITAL MANAGEMENT LLC1.83%
MORGAN STANLEY1.19%
Cornerstone Capital, Inc.1.19%
BARD ASSOCIATES INC1.09%
RENAISSANCE TECHNOLOGIES LLC0.71%
GEODE CAPITAL MANAGEMENT, LLC0.65%
Mesirow Financial Investment Management, Inc.0.55%
HighTower Advisors, LLC0.55%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.21%
VANGUARD EXTENDED MARKET INDEX FUND0.62%
Fidelity Extended Market Index Fund0.30%
iShares Micro-Cap ETF0.16%
Fidelity Total Market Index Fund0.11%
Fidelity Series Total Market Index Fund0.09%
Dimensional U.S. Core Equity 2 ETF0.04%
U.S. Sustainability Core 1 Portfolio0.03%
Fidelity Nasdaq Composite Index Fund0.03%
U.S. CORE EQUITY 2 PORTFOLIO0.03%

OakChart. NEPH. Cached 15 minutes.